Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Blood

Volumn 129, Issue 3, 2017, Pages 347-357

  Theunissen, Prisca ^a   Mejstrikova, Ester ^b   Sedek, Lukasz ^c   Van Der Sluijs Gelling, Alita J ^d   Gaipa, Giuseppe ^e   Bartels, Marius ^f   Sobral da Costa, Elaine ^g   Kotrová, Michaela ^b   Novakova, Michaela ^b,f   Sonneveld, Edwin ^d   Buracchi, Chiara ^e   Bonaccorso, Paola ^e   Oliveira, Elen ^g   Te Marvelde, Jeroen G ^k   Szczepanski, Tomasz ^c   Lhermitte, Ludovic ^h   Hrusak, Ondrej ^b   Lecrevisse, Quentin ⁱ   Grigore, Georgiana Emilia ^j   Froňková, Eva ^b   Trka, Jan ^b   Brüggemann, Monika ^f   Orfao, Alberto ⁱ   Van Dongen, Jacques J M ^a   Van Der Velden, Vincent H J ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d DCOG Dutch Childhood Oncology Group   (Netherlands)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^h CNRS   (France)

ⁱ UNIVERSITY OF SALAMANCA   (Spain)

^j Cytognos SL   (Spain)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD123 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FLUOROCHROME; LEUKOCYTE ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER PATIENT; CELL COUNT; CHILD; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMOLYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NEWBORN; PRE B LYMPHOCYTE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; CLINICAL TRIAL; GENE REARRANGEMENT; GENETICS; MIDDLE AGED; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; SENSITIVITY AND SPECIFICITY; STANDARDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, B-CELL; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 85018677964     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-07-726307     Document Type: Article

References (47)

1. Flohr T, Schrauder A, Cazzaniga G, et al; International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4): 771-782.
2. van der Velden VH, Cazzaniga G, Schrauder A, et al; European Study Group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4): 604-611.
3. van der Velden VH, van Dongen JJ. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol. 2009;538:115-150.
4. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168-5174.
5. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126(8):964-971.
6. Cheng SH, Lau KM, Li CK, et al. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction. PLoS One. 2013;8(7):e69467.
7. Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010; 115(23):4657-4663.
8. Weng XQ, Shen Y, Sheng Y, et al. Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. Blood Cancer J. 2013;3:e133.
9. Dworzak MN, Fröschl G, Printz D, et al; Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6): 1952-1958.
10. Denys B, van der Sluijs-Gelling AJ, Homburg C, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2013;27(3):635-641.
11. Ryan J, Quinn F, Meunier A, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol. 2009;144(1):107-115.
12. Gaipa G, Cazzaniga G, Valsecchi MG, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for for minimal residual disease detection in childhood acute lymphoblasticleukemia. Haematologica. 2012;97:1582-1593.
13. Thörn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol. 2011;152(6):743-753.
14. Karawajew L, Dworzak M, Ratei R, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica. 2015; 100(7):935-944.
15. Shaver AC, Greig BW, Mosse CA, Seegmiller AC. B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model. Am J Clin Pathol. 2015; 143(5):716-724.
16. Pedreira CE, Costa ES, Almeida J, et al; EuroFlow Consortium. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A. 2008;73A(12):1141-1150.
17. Pedreira CE, Costa ES, Barrena S, et al; EuroFlow Consortium. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A. 2008;73(9):834-846.
18. van Dongen JJ, Lhermitte L, Böttcher S, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-1975.
19. Kalina T, Flores-Montero J, van der Velden VH, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012; 26(9):1986-2010.
20. Aalbers AM, van den Heuvel-Eibrink MM, Baumann I, et al. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica. 2015;100(3):315-323.
21. Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31-39.
22. van der Velden VHJ, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJM. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia. 2002;16(5):928-936.
23. van der Velden VHJ, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJM. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia. 2002;16(7):1372-1380.
24. van der Velden VH, de Bie M, van Wering ER, van Dongen JJ. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica. 2006;91(5):679-682.
25. Szczepanski T, van der Velden VHJ, Hoogeveen PG, et al. Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood. 2004;103(10):3798-3804.
26. Brüggemann M, van der Velden VHJ, Raff T, et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia. 2004; 18(4):709-719.
27. Kotrova M, Muzikova K, Mejstrikova E, et al. The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood. 2015;126(8): 1045-1047.
28. Lucio P, Gaipa G, van Lochem EG, et al; BIOMED-I. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted action investigation of minimal residual disease in acute leukemia: international standardization and clinical evaluation. Leukemia. 2001;15(8):1185-1192.
29. Lúcio P, Parreira A, van den Beemd MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia. 1999;13(3):419-427.
30. Mejstríková E, Fronková E, Kalina T, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer. 2010;54(1):62-70.
31. Veltroni M, De Zen L, Sanzari MC, et al; I-BFM-ALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica. 2003; 88(11):1245-1252.
32. Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011; 117(23):6267-6276.
33. Solly F, Angelot F, Garand R, et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. Cytometry A. 2012; 81(1):17-24.
34. Vaskova M, Kovac M, Volna P, et al. High expression of cytoskeletal protein drebrin in TEL/ AML1pos B-cell precursor acute lymphoblastic leukemia identified by a novel monoclonal antibody. Leuk Res. 2011;35(8):1111-1113.
35. Vaskova M, Mejstrikova E, Kalina T, et al. Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia. Leukemia. 2005;19(5):876-878.
36. Wang W, Gao L, Li Y, et al. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(5):1174-1181.
37. van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996-4009.
38. Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood. 1996;87(3):1134-1139.
39. Jansen MW, Corral L, van der Velden VH, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia. 2007;21(4):633-641.
40. Kalina T, Vaskova M, Mejstrikova E, et al. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer. 2005;5:38-49.
41. Kiyokawa N, Iijima K, Tomita O, et al. Significance of CD66c expression in childhood acute lymphoblastic leukemia. Leuk Res. 2014;38(1):42-48.
42. Djokic M, Björklund E, Blennow E, Mazur J, Söderhäll S, Porwit A. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica. 2009; 94(7):1016-1019.
43. Cherian S, Miller V, McCullouch V, Dougherty K, Fromm JR, Wood BL. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry B Clin Cytom. In press.
44. van Lochem EG, van der Velden VHJ, Wind HK, te Marvelde JG, Westerdaal NAC, van Dongen JJM. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004;60(1):1-13.
45. Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90(1): 47-53.
46. Fronkova E, Muzikova K, Mejstrikova E, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant. 2008;42(3):187-196.
47. van der Velden VH, Wijkhuijs JM, van Dongen JJ. Non-specific amplification of patient-specific Ig/ TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia. 2008; 22(3):641-644.